ibrutinib and venetoclax: a powerful combination in frontline and relapsed cll
Published 6 years ago • 287 plays • Length 1:28Download video MP4
Download video MP3
Similar videos
-
2:00
obinutuzumab, ibrutinib, and venetoclax in high-risk cll: the cll2-give and cll13 trials
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients
-
1:47
ash cll highlights: ibrutinib-venetoclax combination & undetectable mrd in ighv-mutated patients
-
2:43
outcomes in high-risk cll patients following fixed-duration treatment with ibrutinib plus venetoclax
-
1:02
combination therapies in cll: ibrutinib and venetoclax
-
1:23
interim analysis of the flair study: efficacy of ibrutinib plus venetoclax in ighv unmutated cll
-
2:18
first-line ibrutinib and venetoclax in cll
-
1:56
ibrutinib plus venetoclax for first-line treatment of cll: 4-year follow-up data
-
2:49
results from the phase iii echo trial of acalabrutinib plus br in mcl
-
3:28
the sympatico trial: ibrutinib plus venetoclax in tp53-mutated mcl
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
1:49
venetoclax in combination with ibrutinib: can it control cll?
-
2:45
optimizing the combination of ibrutinib plus venetoclax in cll
-
1:13
monitoring patients with cll on ibrutinib-based therapies
-
3:18
venetoclax and ibrutinib and drug combinations for cll
-
5:54
updates from captivate: ibrutinib and venetoclax for cll
-
1:56
emerging ibrutinib-based combinations in cll
-
1:36
improve study update: safety and efficacy of venetoclax retreatment in r/r cll
-
5:34
venetoclax added to ibrutinib in patients with cll with molecular resistance to btki treatment
-
2:21
captivate: ibrutinib and venetoclax in cll
-
1:46
novel agent combinations for cll: ibrutinib, venetoclax, obinutuzumab and zanubrutinib
-
1:36
obinutuzumab plus ibrutinib and venetoclax treatment continues to yield high response rates in cll